NAS:ABEO (USA) Also trade in: Germany UK

Abeona Therapeutics Inc

$ 3.74 -0.1 (-2.6%)
Volume: 376,542 Avg Vol (1m): 596,454
Market Cap $: 183.85 Mil Enterprise Value $: 115.54 Mil
P/E (TTM): 0.00 P/B: 1.51
Earnings Power Value -2.53
Net Current Asset Value 0.49
Tangible Book 0.91
Projected FCF -2.14
Median P/S Value 0.66
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 5.4/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt No Debt
Cash-To-Debt range over the past 10 years
Min: 0.03, Med: 1.24, Max: 10000
Current: 10000
0.03
10000
Equity-to-Asset 0.77
Equity-to-Asset range over the past 10 years
Min: -118.34, Med: -0.1, Max: 0.97
Current: 0.77
-118.34
0.97
Debt-to-EBITDA -0.48
Debt-to-EBITDA range over the past 10 years
Min: -1.21, Med: -0.58, Max: -0.17
Current: -0.48
-1.21
-0.17
Piotroski F-Score 2
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -2.02
DISTRESS
GREY
SAFE
Beneish M-Score -4.06
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC -140.09%
WACC 7.86%

Profitability & Growth : 1/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % -7368.85
Operating Margin range over the past 10 years
Min: -7368.85, Med: -1697.98, Max: -98
Current: -7368.85
-7368.85
-98
Net Margin % -7171.11
Net Margin range over the past 10 years
Min: -7171.11, Med: -1728.62, Max: 217.87
Current: -7171.11
-7171.11
217.87
ROE % -45.59
ROE range over the past 10 years
Min: -45.59, Med: -31.75, Max: -20.3
Current: -45.59
-45.59
-20.3
ROA % -39.58
ROA range over the past 10 years
Min: -602.71, Med: -36.21, Max: 379.77
Current: -39.58
-602.71
379.77
ROC (Joel Greenblatt) % -797.74
ROC (Joel Greenblatt) range over the past 10 years
Min: -523920, Med: -7131.82, Max: 72738.46
Current: -797.74
-523920
72738.46
3-Year Total Revenue Growth Rate 42.30
3-Year Revenue Growth Rate range over the past 10 years
Min: 0, Med: -65.2, Max: 198.1
Current: 18.4
0
198.1
3-Year Total EBITDA Growth Rate -57.20
N/A
3-Year EPS w/o NRI Growth Rate -30.90
N/A

» ABEO's 30-Y Financials

Financials (Next Earnings Date: 2019-08-09)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:ABEO

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325413    SIC : 2834
Compare XTAE:CGEN BOM:512529 LSE:ARIX TPE:4142 NAS:CERC NAS:CHMA NAS:PIRS NAS:UROV OTCPK:ABVC XKRX:086820 NAS:ADMA TPE:1760 ASX:MVF XKRX:226950 LSE:BVXP XKRX:299660 WAR:SLV NAS:REPH XKRX:268600 XKLS:7090
Traded in other countries PCJP.Germany 0H7R.UK
Address 3333 Lee Parkway, Suite 600, Dallas, TX, USA, 75219
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. The gene therapy involves the use of DNA as a potential therapy to treat a disease. The company's initial programs are focused on lysosomal storage diseases such as Mucopolysaccharidosis (MPS) IIIA and IIIB.

Ratios

Current vs industry vs history
PB Ratio 1.51
PB Ratio range over the past 10 years
Min: 1.16, Med: 2.99, Max: 55.44
Current: 1.51
1.16
55.44
PS Ratio 415.55
PS Ratio range over the past 10 years
Min: 1.27, Med: 73, Max: 905.56
Current: 415.55
1.27
905.56
EV-to-EBIT -1.73
EV-to-EBIT range over the past 10 years
Min: -5717.9, Med: -4.8, Max: 2
Current: -1.73
-5717.9
2
EV-to-EBITDA -1.83
EV-to-EBITDA range over the past 10 years
Min: -5849.9, Med: -5, Max: 2
Current: -1.83
-5849.9
2
EV-to-Revenue 124.11
EV-to-Revenue range over the past 10 years
Min: 1.2, Med: 82.6, Max: 809.4
Current: 124.11
1.2
809.4
Current Ratio 3.35
Current Ratio range over the past 10 years
Min: 0.02, Med: 1.44, Max: 27.83
Current: 3.35
0.02
27.83
Quick Ratio 3.35
Quick Ratio range over the past 10 years
Min: 0.02, Med: 1.44, Max: 27.83
Current: 3.35
0.02
27.83
Days Sales Outstanding 14.90
Days Sales Outstanding range over the past 10 years
Min: 9.86, Med: 43.51, Max: 69.62
Current: 14.9
9.86
69.62

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -13.20
3-Year Share Buyback Rate range over the past 10 years
Min: -328.9, Med: -13.2, Max: 0
Current: -13.2
-328.9
0

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 4.11
Price-to-Tangible-Book range over the past 10 years
Min: 3.14, Med: 5.55, Max: 1250
Current: 4.11
3.14
1250
Price-to-Median-PS-Value 5.67
Price-to-Median-PS-Value range over the past 10 years
Min: 0.02, Med: 1.1, Max: 776.4
Current: 5.67
0.02
776.4
Earnings Yield (Joel Greenblatt) % -57.59
Earnings Yield (Greenblatt) range over the past 10 years
Min: -404.5, Med: -19.25, Max: 380.9
Current: -57.59
-404.5
380.9

More Statistics

Revenue (TTM) (Mil) $ 0.93
EPS (TTM) $ -1.4
Beta 1.06
Volatility % 45.24
52-Week Range $ 3.73 - 15.65
Shares Outstanding (Mil) 47.94

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 2
Positive ROA N
Positive CFROA N
Higher ROA yoy N
CFROA > ROA Y
Lower Leverage yoy Y
Higher Current Ratio yoy N
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy N